Rappler (Philippines)
중도 성향
기타
Jinggoy’s ailments across 3 plunder cases — from heart to shoulders to knees
Rappler traces the ailments raised by Estrada before the court as he faces different corruption cases through the years
"AILMENTS" · 총 8건
필터 보기현재 지수
50.3
0 = 부정 우세
50 = 중립
100 = 긍정 우세
최근 7일 기준 84,721건을 분석한 결과, 뉴스 심리지수는 50.3(균형)입니다. 긍정 4,287건(5.1%)·중립 78,429건(92.6%)·부정 2,005건(2.4%)이며, 중립 비중이 뚜렷하게 높습니다. 성향 지수는 종합 15.0(중도 균형)입니다.
Rappler traces the ailments raised by Estrada before the court as he faces different corruption cases through the years
Renowned Malayalam actor and director Salim Kumar has passed away at 56 after a cardiac arrest. Battling multiple health issues including liver cirrhosis and kidney ailments, the National Award winner was on ventilator support. His demise has deeply saddened the film industry and fans, who remember his versatile performances, from hilarious comedy to poignant drama.
• Targets entire family of viruses, animal-borne strains; aims to thwart future pandemics; initial-phase trials of 39 participants succeeded; larger efficacy studies loom • Experts hail move as ‘pivotal leap’ for humanity • Approach could end need for regular flu vaccine updates A “FUNDAMENTALLY new” vaccine designed entirely by artificial intelligence has been tested in people for the first time, in what researchers at the University of Cambridge describe as a potential breakthrough in the effort to prevent future pandemics, BBC reported. This experimental approach seeks to establish immunity against a broad range of viruses, including all known coronaviruses, rather than targeting a single circulating strain. Traditional vaccine development typically relies on a currently circulating viral strain. However, certain viruses are adept at mutating, causing conventional vaccines to lose efficacy quickly. This is why seasonal flu and Covid shots require regular updates. “We’re always behind,” Professor Jonathan Heeney of Cambridge told the BBC, noting his team’s goal is to reverse this dynamic. “What we’re trying to do is get ahead of the curve.” The researchers claim it is the first time a vaccine’s key component has been designed entirely by AI and then trialled in people. To achieve this, researchers compiled genetic codes — the biological instruction manuals — from coronaviruses documented by global surveillance programs. An AI system analysed these sequences to design a “super-antigen.” Antigens are essential components of vaccines that train the immune system to attack foreign invaders. This super-antigen trains the immune system to defend against the entire family of viruses, providing immunity even if viruses mutate or a new infection jumps from animals to humans. The technology is “surprising all of us”, Heeney said, adding it is “amazing what we can do with it for the good of humanity”. “This is about making vaccines that protect us, not just from today’s viruses, but protect us from what can cause the next outbreak or disease,” Heeney said. “This is a fundamental shift in how we prepare for pandemics.” Initial trials involving 39 participants assessed safety. A subsequent study of approximately 200 individuals will test how effectively the vaccine stimulates the immune system. Findings published in the Journal of Infection indicated that the impact on the immune system was “modest,” yet the results continue to generate excitement. Prof Saul Faust of the University of Southampton, who led some of the trial work, said the AI-driven approach “definitely has potential” and described it as “really exciting”. “What’s really interesting is the technology is an awful lot better at designing vaccines for potential pandemics when viruses are changing,” he said. While coronavirus research remains in early stages, the team is leveraging the technology to develop vaccines for other ailments. According to the report, they are conducting animal research into a universal seasonal flu vaccine to eliminate the need for annual updates. They are also developing a vaccine for the H5N1 bird flu. Researchers are also exploring inoculations for viral hemorrhagic fevers, including Ebola species. The BBC highlighted that the ongoing outbreak in the Democratic Republic of Congo is caused by an Ebola species currently lacking a targeted vaccine. Professor Andy Pollard, director of the Oxford Vaccine Group, who was not involved in the Cambridge study, told the outlet that the methodology is producing compelling evidence. “It’s fascinating data, and people wouldn’t have predicted they’d be able to generate these immune responses,” Pollard said. Pollard cautioned that human trials will determine success, as human immune systems differ from those of laboratory mice. Broadly, Pollard characterised AI as a “game changer” for vaccine research, predicting it will accelerate development and “save lives”. Professor Marian Knight, scientific director for the National Institute for Health and Care Research, described the trial as a “pivotal leap forward in our ability to deliver broad, lasting viral protection”. “Another British science success story, this is a great example of how we can bring our research expertise together with AI to deliver new treatments,” UK’s Science Minister Lord Vallance said. “With the first human trials showing positive results, this work could help speed up the rollout of vaccines to benefit people all over the world for the long term.” Published in Dawn, June 6th, 2026
Despite a diminished federal presence, public health departments are preparing for common ailments that could afflict fans who gather for the event — and are keeping an eye on the Ebola outbreak, too.
A regulatory overhaul of India’s grid has sparked fears in the solar power industry that they may suffer a negative impact on profitability. The overhaul includes a stipulation regarding penalties for solar generators if they fail to deliver the electricity that they have committed to supply to the grid, Reuters reported. India's electricity grid is expanding at a slower pace than the boom in solar energy installations, leading to an increased share of solar curtailments and threatening to slow the solar and wind boom in the world's most…
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.
South Korean international Hwang In-beom has spent most of the past half year rehabbing assorted injuries. The midfielder for Feyenoord in the top Dutch league hurt his calf in September, his thigh in November and then his ankle in March. The last of those ailments knocked Hwang out for the rest of his club season, a cause for concern for the national team that has been relying heavily on the 29-year-old midfielder. In a bid to get him back to health for the FIFA World Cup that kicks off June 11